Vial - lyophilised powderSubcutaneous (SQ)5 mg

Ipamorelin is researched for its ability to prompt the body's own growth hormone release. It attracts interest because its signalling profile differs from some older compounds in the category. The conversation often includes recovery and body composition, but those goals need their own evidence rather than assumptions from hormone changes.

Shipping Information
Shipping Information

Free Shipping

Decor Outdoor offers free regular shipping on all orders shipped to residential or commercial addresses within the contiguous United States. Orders are delivered Monday through Friday (excluding holidays).

Drop Shipping

We are an online-only luxury furniture and lighting boutique, and do not have a warehouse. Consequently, all orders are drop shipped directly from our manufacturers to your door. If your order includes items from more than one manufacturer, you will receive multiple deliveries. Because we are dependent on the on-hand inventory of our manufacturing partners, some items listed on our site may not actually be available right away. Please call us at 888.784.4644 or via our contact form with any stocking questions and we'll get in touch with the appropriate manufacturer for answers, before you place your order.

Ground Shipping

Small parcel items ship regular ground via delivery services such as FedEx, UPS or DHL. Orders typically take 2-3 business days to process and in-stock items will usually be delivered 3-5 days from the date that they ship (depending on origin and destination). If there is a delay, you will be notified by email. No signature is required for standard ground shipping, so you may want to make arrangements to have packages brought inside soon after delivery, if you are unable to receive it in person.
Storage & Handling

Follow the storage instructions on your product label and the information supplied with your batch. Storage and handling requirements vary by product and presentation.

Ipamorelin works through a receptor involved in growth hormone release. Early research drew attention to its more selective hormone response compared with some older compounds.

Where It Fits

Growth hormone signalling research. Claims about recovery, sleep or body composition need direct supporting evidence.

The PHI Perspective

A more selective mechanism is worth understanding. It does not remove the need for a clear purpose, appropriate assessment and evidence of benefit.

For clinician-directed use only where permitted.

How It Works

It acts on the ghrelin receptor, one of the signals involved in prompting growth hormone release. It is not growth hormone itself.

What the Research Suggests

Human development generated meaningful safety and pharmacology data, including later-stage clinical work in a different indication. The programme did not establish efficacy for recovery, body composition or healthy ageing.

Evidence level: B. Phase III human safety data; efficacy endpoint not met, different indication

Storage & Handling

Store lyophilised vial at 2-8 C, protected from light.

Active compound: Ipamorelin

Mechanism of Action

Binds the growth hormone secretagogue receptor (GHS-R1a), the ghrelin receptor, on pituitary somatotrophs. Stimulates growth hormone release directly and reduces somatostatin inhibitory tone. Its receptor selectivity accounts for the absence of significant cortisol and prolactin elevation seen with less selective secretagogues.

Clinical Evidence Base

Well-characterised preclinical pharmacology establishing selectivity. Human Phase II and III trials in postoperative ileus demonstrated acceptable tolerability but did not meet efficacy endpoints. No controlled trials for body composition, recovery or ageing endpoints.

Safety & Precautions

Generally well tolerated in trials. Reported effects include injection-site reactions, headache, lightheadedness and increased appetite reflecting ghrelin-receptor activity. Sustained growth hormone elevation may produce fluid retention, arthralgia and reduced insulin sensitivity. Contraindicated where malignancy is present or suspected. IGF-1 and glucose monitoring is advised in continued use.

Contraindications

Active or suspected malignancy; pregnancy and breastfeeding; proliferative diabetic retinopathy; acute critical illness; known hypersensitivity.

Literature & References

Raun K et al. Eur J Endocrinol, 1998 - ipamorelin, the first selective growth hormone secretagogue. | Beck DE et al. Am J Surg, 2014 - Phase III evaluation in postoperative ileus. | Gobburu JV et al. Pharm Res, 1999 - pharmacokinetic-pharmacodynamic modelling of ipamorelin.

Select the fields to be shown. Others will be hidden. Drag and drop to rearrange the order.
  • Image
  • SKU
  • Rating
  • Price
  • Stock
  • Availability
  • Add to cart
  • Description
  • Content
  • Weight
  • Dimensions
  • Additional information
Click outside to hide the comparison bar
Compare